Safety

R&D

Should traditional safety considerations be treated as distinct from broader ESG frameworks, or fully integrated within them?

News

Johnson & Johnson has made a $5.5bn bid to finally bring more than 15 years of litigation over the safety of its talcum powder products to a close.

News

Against the advice of FDA staff scientists, an advisory committee has narrowly voted in support of looser restrictions on compounded peptides.

News

EU pharmaceutical safety advisers have said that commonly used contraceptives may carry a small risk of a type of brain cancer with prolonged use.

News

Pressure is building on Amgen to withdraw rare disease therapy Tavneos, after the CHMP recommended its marketing authorisation by revoked in the EU.

R&D

Institutional Review Boards (IRBs) play a key role in evaluating scientific integrity and participant safety.